On March 18, 2026, TG Therapeutics, Inc. (the "Company") entered into a significant financing agreement amendment, establishing a $750 million term loan facility. This facility was fully borrowed on the closing date, with a portion of the proceeds allocated to repay existing initial term loans. The new term loan, referred to as the "2026 Term Loan," is set to mature on March 18, 2031, and will accrue interest based on a margin plus a base rate or Term SOFR. The applicable margin will be determined quarterly based on the Company's total net leverage ratio. The agreement also includes an uncommitted additional facility of up to $250 million. This financing arrangement is secured by a lien on substantially all assets of the Company and its subsidiaries, and it contains customary covenants and representations. The events of default under the financing agreement are standard for such transactions, allowing the administrative agent to take enforcement actions if necessary. This strategic move is expected to enhance the Company's liquidity position and provide the necessary capital for ongoing operations and potential growth initiatives.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.